Evidence map›Paper›PMID 27194317›Full record

Trial reportBMJ open2016

Protocol for Care After Lymphoma (CALy) trial: a phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care.

Karen Taylor, David Joske, Max Bulsara, Caroline Bulsara, Leanne Monterosso

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karen TaylorWestern Australia Cancer and Palliative Care Network, Perth, Western Australia, Australia School of Nursing and Midwifery and Centre for Nursing and Midwifery Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.ORCID 0000-0001-9586-9427
David JoskeSir Charles Gairdner Hospital, Nedlands, Western Australia, Australia School of Medicine, University of Western Australia, Crawley, Western Australia, Australia.
Max BulsaraInstitute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.
Caroline BulsaraSchool of Nursing and Midwifery and Centre for Nursing and Midwifery Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.
Leanne MonterossoSchool of Nursing and Midwifery and Centre for Nursing and Midwifery Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia St John of God Hospital, Murdoch, Western Australia, Australia School of Nursing, Edith Cowan University, Joondalup, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLymphoma is the sixth most common cancer diagnosed in Australia and internationally. Owing to the aggressive nature of the disease and intensity of treatment, survivors face long-term effects that impact on quality of life. Current models of follow-up post-treatment fail to address these complex issues. Given that 74% of patients with lymphoma cancer now survive 5 years beyond diagnosis and treatment, it is important to address this gap in care.

aimTo determine self-reported informational and practical needs, anxiety, depression, stress, coping and empowerment at baseline, 3 and 6 months. METHODS AND ANALYSIS: A pilot randomised controlled trial will test the effect of a nurse-led lymphoma survivorship clinic compared with usual post-treatment care at a large tertiary cancer centre in Western Australia. The intervention will comprise three face-to-face appointments with delivery of tailored resources, a survivorship care plan and treatment summary (SCP TS). The SCP TS will be given to the participant and general practitioner (GP). Intervention participants will be interviewed at completion to explore the perceived value of the intervention components and preferred dose. An evaluation developed for GPs will assess receipt and use of SCP TS. The primary intent of analysis will be to address the feasibility of a larger trial and requisite effect and sample size. ETHICS AND DISSEMINATION: Ethics approval has been granted by the University of Notre Dame Australia and Sir Charles Gairdner Hospital in Western Australia. Peer-reviewed publications and conference presentations will report the results of this phase II trial. TRIAL REGISTRATION NUMBER: ANZCTRN12615000530527; Pre-results.

Indexed as

Needs AssessmentPatient Care PlanningPatient Education as TopicAftercareAustraliaCancer SurvivorsCommunicationFeasibility StudiesHumansLymphomaModels, NursingPilot ProjectsPractice Patterns, Nurses'Research Designmodels of carenurse-led interventionsurvivorship

Identifiers

PMID27194317
PMCPMC4874152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.